volume 20 pages 46-53

AMPA receptor potentiators: from drug design to cognitive enhancement

Publication typeJournal Article
Publication date2015-02-01
scimago Q1
wos Q1
SJR1.304
CiteScore10.3
Impact factor4.2
ISSN14714892, 14714973
Drug Discovery
Pharmacology
Abstract
Positive allosteric modulators of ionotropic glutamate receptors have emerged as a target for treating cognitive impairment and neurodegeneration, but also mental illnesses such as major depressive disorder. The possibility of creating a new class of pharmaceutical agent to treat refractive mental health issues has compelled researchers to redouble their efforts to develop a safe, effective treatment for memory and cognition impairments. Coupled with the more robust research methodologies that have emerged, including more sophisticated high-throughput-screens, higher resolution structural biology techniques, and more focused assessment on pharmacokinetics, the development of positive modulators of AMPA receptors holds great promise. We describe recent approaches that improve our understanding of the basic physiology underlying memory and cognition, and their application toward promoting human health.
Found 
Found 

Top-30

Journals

1
2
3
4
5
Mendeleev Communications
5 publications, 5.68%
Molecules
3 publications, 3.41%
International Journal of Molecular Sciences
3 publications, 3.41%
Molecular Pharmacology
2 publications, 2.27%
Biomolecules
2 publications, 2.27%
Journal of Medicinal Chemistry
2 publications, 2.27%
Pharmacological Reviews
1 publication, 1.14%
Journal of Pharmacology and Experimental Therapeutics
1 publication, 1.14%
Current Molecular Pharmacology
1 publication, 1.14%
Praxis
1 publication, 1.14%
Behavioural Pharmacology
1 publication, 1.14%
Journal of Psychopharmacology
1 publication, 1.14%
Nutrients
1 publication, 1.14%
Pharmaceutics
1 publication, 1.14%
Pharmaceuticals
1 publication, 1.14%
Translational Psychiatry
1 publication, 1.14%
Neuropsychopharmacology
1 publication, 1.14%
Scientific Reports
1 publication, 1.14%
Psychopharmacology
1 publication, 1.14%
Nature Communications
1 publication, 1.14%
Translational Neurodegeneration
1 publication, 1.14%
PLoS ONE
1 publication, 1.14%
Biophysical Journal
1 publication, 1.14%
Structure
1 publication, 1.14%
Current Opinion in Structural Biology
1 publication, 1.14%
Cell
1 publication, 1.14%
Multiple Sclerosis and Related Disorders
1 publication, 1.14%
Neuroscience and Biobehavioral Reviews
1 publication, 1.14%
Journal of Chemical Neuroanatomy
1 publication, 1.14%
1
2
3
4
5

Publishers

2
4
6
8
10
12
14
16
Elsevier
15 publications, 17.05%
Springer Nature
13 publications, 14.77%
MDPI
11 publications, 12.5%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
5 publications, 5.68%
Wiley
5 publications, 5.68%
American Chemical Society (ACS)
5 publications, 5.68%
American Society for Pharmacology and Experimental Therapeutics
4 publications, 4.55%
Cold Spring Harbor Laboratory
4 publications, 4.55%
Royal Society of Chemistry (RSC)
2 publications, 2.27%
Taylor & Francis
2 publications, 2.27%
Frontiers Media S.A.
2 publications, 2.27%
Bentham Science Publishers Ltd.
1 publication, 1.14%
Hogrefe Publishing Group
1 publication, 1.14%
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.14%
SAGE
1 publication, 1.14%
Public Library of Science (PLoS)
1 publication, 1.14%
American Society for Biochemistry and Molecular Biology
1 publication, 1.14%
Social Science Electronic Publishing
1 publication, 1.14%
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 1.14%
Pleiades Publishing
1 publication, 1.14%
Scientific Research Publishing
1 publication, 1.14%
European Molecular Biology Organization
1 publication, 1.14%
Annual Reviews
1 publication, 1.14%
American Diabetes Association
1 publication, 1.14%
Institute of Biochemistry
1 publication, 1.14%
Medknow
1 publication, 1.14%
Hacettepe University Journal of the Faculty of Pharmacy
1 publication, 1.14%
Society for Neuroscience
1 publication, 1.14%
2
4
6
8
10
12
14
16
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
88
Share
Cite this
GOST |
Cite this
GOST Copy
Partin K. M. AMPA receptor potentiators: from drug design to cognitive enhancement // Current Opinion in Pharmacology. 2015. Vol. 20. pp. 46-53.
GOST all authors (up to 50) Copy
Partin K. M. AMPA receptor potentiators: from drug design to cognitive enhancement // Current Opinion in Pharmacology. 2015. Vol. 20. pp. 46-53.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.coph.2014.11.002
UR - https://doi.org/10.1016/j.coph.2014.11.002
TI - AMPA receptor potentiators: from drug design to cognitive enhancement
T2 - Current Opinion in Pharmacology
AU - Partin, Kathryn M.
PY - 2015
DA - 2015/02/01
PB - Elsevier
SP - 46-53
VL - 20
PMID - 25462292
SN - 1471-4892
SN - 1471-4973
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2015_Partin,
author = {Kathryn M. Partin},
title = {AMPA receptor potentiators: from drug design to cognitive enhancement},
journal = {Current Opinion in Pharmacology},
year = {2015},
volume = {20},
publisher = {Elsevier},
month = {feb},
url = {https://doi.org/10.1016/j.coph.2014.11.002},
pages = {46--53},
doi = {10.1016/j.coph.2014.11.002}
}